{"name":"Prime Gene Therapeutics Co., Ltd.","slug":"prime-gene-therapeutics-co-ltd","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Immunology","slug":"immunology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"PG-011Gel","genericName":"PG-011Gel","slug":"pg-011gel","indication":"Treatment of severe combined immunodeficiency (SCID)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Placebo (twice daily)","genericName":"Placebo (twice daily)","slug":"placebo-twice-daily","indication":"Other","status":"phase_3"}]}],"pipeline":[{"name":"PG-011Gel","genericName":"PG-011Gel","slug":"pg-011gel","phase":"phase_3","mechanism":"PG-011Gel is a gene therapy that targets the underlying cause of certain diseases.","indications":["Treatment of severe combined immunodeficiency (SCID)"],"catalyst":""},{"name":"Placebo (twice daily)","genericName":"Placebo (twice daily)","slug":"placebo-twice-daily","phase":"phase_3","mechanism":"Placebo produces no pharmacological effect and serves as an inert control in clinical trials.","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTFB1N2d4NnYwN0JiU181Tm9vV0dUM1c1NWVMUHNCdlZFVmRSZXpmRFp3TnBQUVJXYnFYV1VlNVBIZXU0TzY4bE5BNTd4NGpIT21aYlZHMy1qSW1HWDFH?oc=5","date":"2026-04-06","type":"pipeline","source":"BioSpace","summary":"Layoff Tracker: BioNTech Will Close Singapore Plant, Affecting 85 Employees - BioSpace","headline":"Layoff Tracker: BioNTech Will Close Singapore Plant, Affecting 85 Employees","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiogFBVV95cUxNZVROZm9jVHZrZmV3YlZOYnVSc2hTX2hkdFQ2cU05OV9uV2xqVDNuMjhWU1o1bFoxRGZJUi1oSl81U2ZXRDZVdV9HQmd1Z2NHQW1tVVZVNWJQbW5DSEstSGhIa2x4eDllXzZqbVRuSjA4Z0VUSTZIdnpJSTZ6Sk5ScVljUGgwU0RwWmtVU0V5cjI2NFFqWlBqcGJfYVZUZTJ3S3c?oc=5","date":"2026-03-04","type":"regulatory","source":"BioPharma Dive","summary":"Prime to test FDA flexibility with 2-patient gene editing submission - BioPharma Dive","headline":"Prime to test FDA flexibility with 2-patient gene editing submission","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxNY1habWQ2cTM4YlY2M3VxMmp2RXZCb0lNV0c0R0I4WjdiTTNvRFNYeVFWdXlBR2RzbzUwRnA1eXY5ZDQzVlc4cGk5NWR3V2Zhcm81bTIyN2Y1R2pTNXl0bFl0WnJUTXZGQXNLVmlMb1N1SHRyZVFNcklwMXVQVm9kTFo3RQ?oc=5","date":"2026-02-18","type":"pipeline","source":"Yahoo Finance","summary":"Jacob Funds Bets on Prime Medicine (PRME), a Next-Generation Gene Therapy Company - Yahoo Finance","headline":"Jacob Funds Bets on Prime Medicine (PRME), a Next-Generation Gene Therapy Company","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihgFBVV95cUxNdHg0Yk1JMTYtcEJZejJIZmNCTTRZbzFsRGtDemtZUnpwbTRvTDEtbDRvdGNSMGpRTzJIa0hEUF9oeUJ5cEl6ekRZWE9QVlF2U3RJNzlZSnJ1ekpFOWdfWG51LVFaT1pUejJnNU9sR29TMHlFcXZDQTA1Q0VOX3FiZ2FTSjBOUQ?oc=5","date":"2026-01-13","type":"pipeline","source":"Southwest Ledger","summary":"What does the future of gene therapy market hold? - Southwest Ledger","headline":"What does the future of gene therapy market hold?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTE15dW5nVWlNWlVublVEWE9CWlBWQTlXMmY0UjlPWmo5OW5xdFh2bGtsZmNFYXk3aVVVUlhEV3RET0NhWnEzem9XVDlkcXk5d3V2WlpJ?oc=5","date":"2026-01-12","type":"pipeline","source":"FirstWord Pharma","summary":"Today at JPM: M&A simmers but no sparks, moving on from MFN, and gene therapy's MAHA moment - FirstWord Pharma","headline":"Today at JPM: M&A simmers but no sparks, moving on from MFN, and gene therapy's MAHA moment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxPNEVTNng3TkdFaWY1SlM5Y29meFkxMVZKZE1EQnUzV014Z0o0YWZmMDZtOVFVajhjTzBNM0ZhQUtvdkhpWjVZcThuNUhaSUNOc196NXNSMDhiXzBZN29LdGlWU2RIZ3VVNnBSVUt1cUY4TTJHeURYMmtQUzZGNU9iNEFXVFpOTzRkQ1lNdXBwLU43TldDVjNpZmVYUmRxc1ZVZXRoRHQzYjl1bkk?oc=5","date":"2026-01-02","type":"pipeline","source":"PR Newswire","summary":"Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize - PR Newswire","headline":"Gene Therapy: 5 Biotech Stocks Chasing the $36B Prize","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQaDRGN2g0SldoTmg2anVGdXpRMVRSMXVkRlE5OEVYTGdSV0s1SHhLbDVpT3hEZGhRQzRWT0dPZVpwcWc2Nnprc3NEME03NVBaWHhGV1ZDaFdHM044STdSdmpEZW9kaFc2YnNJd2N1UlRUOExPZnN6aVpNTG9EUEdYTENiMTRwYnYwMDJJ?oc=5","date":"2025-12-01","type":"deal","source":"BioPharma Dive","summary":"Regeneron inks gene editing deal with startup Tessera - BioPharma Dive","headline":"Regeneron inks gene editing deal with startup Tessera","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiZkFVX3lxTFBVQS1YTU1aUTdrRDdfaDk1eTc1RkZObE1IZWE2NUdBX3NzYzF2ejVkNmR5NThLX2VRa2NPVFJXcEN2TTZlZ0pucUxPTE5fVllfUW1wcW82czlRWVc2ZGduX1RtZDhXUQ?oc=5","date":"2025-09-30","type":"pipeline","source":"Labiotech.eu","summary":"CRISPR technology’s next wave: Ten companies to watch in 2025 - Labiotech.eu","headline":"CRISPR technology’s next wave: Ten companies to watch in 2025","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxNc1ZybXNqVnFxUGhoQ2dNVEtwQUpjVF9ybWpfazI0RWtzaFlYelczby16RU9nVHlKR1Y1S1dzMF9VdXNnMDBtQnJJWGJlOHJ3N1JQajI1aHlqQVo1czhxVEdyM01qNE5lXzJYTmVnWnNWOHVtZEVpSGliLUJZMlJyYkJLVzNjUWo3YWE1b21SNEIwYVJqZThlcDNfM3EwRV9qUWFlcGhsZVQ2WWJ1UURkcldjU0MzdE45?oc=5","date":"2025-09-22","type":"trial","source":"Genetic Engineering and Biotechnology News","summary":"StockWatch: Data, Big Name Investors Drive Prime Medicine Stock Surge - Genetic Engineering and Biotechnology News","headline":"StockWatch: Data, Big Name Investors Drive Prime Medicine Stock Surge","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikAFBVV95cUxQZ2JuODRKYTlaS1FpbnhOWVFzSWJhRWQtOFNVXy1tal83Wk1ibmtMLXhXbVQzZGVFN1RUTWpQaW55TC1WeEhPT1Q5Mk5TZzR2X2VrQnpRd0s4QU1MYTRFTnk5X2ZVNVFsUEdwZmY1RUYtTkktMzNULXJrUHlrbllMSDR3V2ZZdi15WnV5cE1hOU8?oc=5","date":"2025-08-11","type":"pipeline","source":"Pharma Voice","summary":"Are stem cell therapies ready for pharma’s prime time? - Pharma Voice","headline":"Are stem cell therapies ready for pharma’s prime time?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuAFBVV95cUxOclVMT2RmU3VvbktyUmNuSFRicXRkTWFNbDg3eFdmRFdZYmxDaWFsckNDc3c2cXJMd01zcGJjN25DSXMxanFZX243MFpBWWdrQ2FfODdXUGRuczhOdS1wYnJ3bGs4bk5vZ1VIRnBMa2FLLTZPeGt0SHpOMUVLTDlyQ0V6eGNmVWs2WjgxWGdRNzl3VHJ0WUxoeVVsZFk2Z0JzSkJZQm1KRUFSQmM5b1JpeUl1M0hGSG5Y?oc=5","date":"2025-05-19","type":"pipeline","source":"Fierce Biotech","summary":"Prime Medicine CEO exits as biotech shelves sole clinical gene therapy, lays off 25% of staff - Fierce Biotech","headline":"Prime Medicine CEO exits as biotech shelves sole clinical gene therapy, lays off 25% of staff","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2025-05-19","type":"pipeline","source":"GlobeNewswire","summary":"Prime Medicine Announces Strategic Restructuring to Focus - GlobeNewswire","headline":"Prime Medicine Announces Strategic Restructuring to Focus","sentiment":"neutral"}],"patents":[],"drugCount":2,"phaseCounts":{"phase_3":2},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}